TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04739683

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley bulb placement
Description: A 16 F Foley catheter with a 30-mL balloon and stylet is inserted into the endocervical canal under direct visualization by sterile speculum exam or by digital palpation. The Foley catheter is advanced to or past the internal os, and the balloon is filled with 30-40 mL of sterile water. The catheter is then placed on genital traction by taping the end of the catheter to the medial portion of the thigh.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DILAPAN-S® placement
Description: A bivalve speculum will be used to visualize and prepare the cervix with an antiseptic solution. The DILAPAN-S® (4 x 65 mm) will be inserted in the cervical canal until it traverses the internal os. As many dilators as needed to achieve the desired effect should be inserted. Specific number of pieces always depends on decision and clinical judgement of physician and indications. A gauze pad moistened with sterile water or saline may be inserted into the vagina to help keep the DILAPAN-S® in place, if needed
Study: NCT05580640

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OMT
Description: For this proof-of-concept study we will use a series of case studies. This will allow us to determine if a single session of OMT can improve gait in subjects with prior knee surgery, whether multiple sessions are required to change chronic compensatory musculoskeletal issues, and whether subtle gait anomalies (or improvements), in patients with knee arthroscopy can be detected with the gait analysis system
Study: NCT06657716

Intervention type: DEVICE
Intervention: ANTERION investigational
Description: Device: ANTERION investigational~Measurements from the investigational device ANTERION with software version 1.5 are to be compared against measurements from the ANTERION with software version 1.2.4 (cleared version)

Intervention type: DEVICE
Intervention: ANTERION investigational
Description: Device: ANTERION investigational~Measurements from the investigational device ANTERION with software version 1.5 are to be compared against measurements from the ANTERION with software version 1.2.4 (cleared version)
Study: NCT06657573

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: An AI-enabled chatbot tailored for influenza vaccine consultation
Description: The AI-enabled influenza vaccine chatbot can be accessed online through WeChat or any web browsers. The foundation of this chatbot is an expansive knowledge database, constructed with information sourced exclusively from healthcare authorities such as China CDCs and Health Departments, and thoroughly verified by public health experts. This database integrates data on the disease's burden, susceptibility, and severity, along with in-depth details about the vaccines, including their importance, efficacy, safety, and recommended demographics and timing for vaccination. It also covers types and costs of vaccines, societal norms such as vaccination guidelines, expert recommendations, and vaccination trends both in China and internationally. It also includes misinformation and fact-checking contents and provides information about vaccination services such as locations and appointment scheduling.
Study: NCT06656182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical and Thoracic SNAGs
Description: cervical SNAGs (C3-C7) and thoracic SNAGs (T1-T12) with 6 repetitions of 1 set three times per week for 4 weeks along with scapular mobilizations of 10 repetitions of 1 set and stretching of trapezius (upper, middle and lower fibers), levator scapulae and rhomboids (major and minor)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional physical therapy and scapular mobilizations
Description: scapular mobilizations of 10 repetitions of 1 set and stretching of trapezius (upper, middle and lower fibers), levator scapulae and rhomboids (major and minor)
Study: NCT06656624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib combined with AI±OFS
Description: Ribociclib: 600mg /d, 3 weeks continuous oral withdrawal for 1 week; AI: Anastrozole 1mg, 1 time /d, oral; Letrozole: 2.5mg, 1 time /d, oral; Exemestane Tablets: 25mg, 1 time /d, oral Goserelin: 3.6 mg every 28 days, subcutaneous injection in the abdomen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: physician's choice of chemotherapy sequential Ribociclib combined with AI±OFS
Description: Docetaxel: 100mg/m2 IV drip every 21 days; Paclitaxel: 175mg/m2 every 21 days, IV drip; Paclitaxel for Injection (Albumin Bound): 100\~150mg/m2 IV drip every 7 days; Capecitabine: 1000mg/m2, 2 times/d, 2 consecutive weeks of oral discontinuation for 1 week; Ribociclib: 600mg /d, 3 weeks continuous oral withdrawal for 1 week; AI: Anastrozole 1mg, 1 time /d, oral; Letrozole: 2.5mg, 1 time /d, oral; Exemestane Tablets: 25mg, 1 time /d, oral Goserelin: 3.6 mg every 28 days, subcutaneous injection in the abdomen.
Study: NCT06656598

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Neoadjuvant treatment with Carboplatin AUC 5 D1 (3 cycles of 4 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Neoadjuvant treatment with Carboplatin AUC 5 D1 (3 cycles of 4 weeks).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Neoadjuvant treatment with Paclitaxel 80mg/m² D1 (3 cycles of 4 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Neoadjuvant treatment with Paclitaxel 80mg/m² D1 (3 cycles of 4 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Neoadjuvant treatment with Cemiplimab (Libtayo®) 350 mg D1-D21 (3 cycles of 4 weeks).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Curative hypofractionated radiotherapy
Description: Curative hypofractionated radiotherapy (55 Gy/20fr) after the end of neoadjuvant treatment.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Curative hypofractionated radiotherapy
Description: Curative hypofractionated radiotherapy (55 Gy/20fr) after the end of neoadjuvant treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cemiplimab (maintenance)
Description: Maintenance immunotherapy with Cemiplimab 350 mg every 3 weeks after the end of radiotherapy (12 months).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab (maintenance)
Description: Maintenance immunotherapy with Cemiplimab 350 mg every 3 weeks after the end of radiotherapy (12 months).
Study: NCT06657625

Intervention type: OTHER
Intervention: Sepsis Performance Improvement Program
Description: Training/awareness for medical and paramedical staff; creation of informational posters; development of an institutional pathway in the emergency department; creation of a protocol ; establishment of a sepsis team with a dedicated contact number.
Study: NCT06587256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mouth Tape
Description: A single piece of silicone tape placed vertically over the lips. When positioned properly the participant can still inhale/exhale and cough around the tape if needed, but will tend to keep mouth closed otherwise.
Study: NCT04728204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Depresijos terapija
Description: Intervention is based on the principles of cognitive behavioral therapy and culturally adapted to elderly Lithuanian population. The main purpose of the intervention is to reduce the symptoms of depression and increase psychological well-being. Intervention contains psychoeducation, examples, exercises and consultation with a psychologist.
Study: NCT04708067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp Alfa
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiation therapy
Study: NCT05516914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBL-007 Injection
Description: Initial dose - MTD; Q3W; intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab Injection
Description: Initial dose; Q3W; intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin Injection
Description: Initial dose；Q3W; intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride for Injection
Description: Initial dose；Q3W; intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel injection
Description: Initial dose；Q3W; intravenous infusion
Study: NCT06533592

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continous suture technique
Description: Duct-to-duct anastomosis will be performed using continuous suture technique for study group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interrupted suture technique
Description: Duct-to-duct anastomosis will be performed using an interrupted suture for control group,
Study: NCT06352177

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Noom Weight Application
Description: This commercially available program (Noom Weight) promotes clinically significant body weight loss and behavior change in multiple populations. The program is delivered through a smartphone application and includes self-monitoring and feedback features for diet, physical activity, and body weight, as well as digital access to a 1:1 behavior change coach, a support group facilitated by a health coach, and a curriculum delivered via daily articles focused on nutrition, physical activity, and sustainable behavioral change.
Study: NCT04634578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: All participants will receive a single intravitreal injection of bevacizumab in one or both eyes following enrollment into the study. The injection/s should be given as soon as possible but no later than 2 days after the diagnosis of type 1 ROP meeting all of the inclusion criteria and none of the exclusion criteria.~Eyes meeting eligibility criteria will receive a single dose of 0.063 mg or 0.25mg bevacizumab provided by the pharmacy at the investigator's institution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: All participants will receive a single intravitreal injection of bevacizumab in one or both eyes following enrollment into the study. The injection/s should be given as soon as possible but no later than 2 days after the diagnosis of type 1 ROP meeting all of the inclusion criteria and none of the exclusion criteria.~Eyes meeting eligibility criteria will receive a single dose of 0.063 mg or 0.25mg bevacizumab provided by the pharmacy at the investigator's institution.
Study: NCT05526534

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: heated humidified high flow nasal cannula oxygen therapy, HFNC
Description: HFNC can accurately provide 21% \~ 100% oxygen concentration through air oxygen mixer. And through the heating and humidification device to provide 37℃, relative humidity of 100% gas, the maximum flow of 70L/min.

Intervention type: DEVICE
Group type: OTHER
Intervention: Nasal cannula oxygen
Description: Nasal cannula oxygen has become a routine part of postoperative treatment
Study: NCT05902728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX208
Description: Subjects will receive treatment HLX208 900 mg in the fast state followed by 7 days washout ，then receive treatment HLX208 900 mg in the fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX208
Description: Subjects will receive treatment HLX208 900 mg in the fed state followed by 7 days washout ，then receive treatment HLX208 900 mg in the fast state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX208
Description: 450 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX208
Description: 900 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg
Description: 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: 600mg
Study: NCT04302324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Given as 500mg oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given as 4mg oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given as 20mg IV and 20mg or 40mg oral tablets
Study: NCT05775653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADAPT program
Description: The ADAPT program is a structured and individualized group-based program, in which two occupational therapists teach groups of people the skills of problem-solving more efficiently as means to overcome ADL task performance problems. The ADAPT program 3.0 includes 10 two-hour sessions and is followed by two booster sessions to support sustainable gains.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: UOT
Description: UOT is delivered by one occupational therapist. Sessions are individualised and focus on improving ADL ability e.g. by practicing the performance of ADL task. UOT typiccally includes 7 one-to-one sessions of 60 minutes, delivered over a 10-week period in the clients´ homes. The dose is however not fixed but based on the occupational therapists´ clinical judgement.
Study: NCT05707169

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saphenous Ablation
Description: Endogenous Laser Ablation (EVLA) uses a laser fibre, which is inserted into the refluxing vein via skin puncture.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saphenous Ablation
Description: Endogenous Laser Ablation (EVLA) uses a laser fibre, which is inserted into the refluxing vein via skin puncture.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endogenous Laser Ablation (EVLA)
Description: Endogenous Laser Ablation (EVLA)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endogenous Laser Ablation (EVLA)
Description: Endogenous Laser Ablation (EVLA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mixture of 20 mL 2% lidocaine, 1: 200,000 adrenaline and 20 mL 0.5% levobupivacaine in 1 L of 0.9% saline
Description: mixture of 20 mL 2% lidocaine, 1: 200,000 adrenaline and 20 mL 0.5% levobupivacaine in 1 L of 0.9% saline
Study: NCT04916678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: R-TEP EMDR intervention
Description: During the intervention period, trained psychologists are available in the ER and will provide preferentially a short early 1-hour R-TEP EMDR intervention for patients selected with high risk of PCLS. Patient's selection will be conducted using a score developed in previous studies. If therapist considers R-TEP EMDR unsuitable, he could provide another type of intervention (such as reassurance) that will be recorded.~When no high-risk patient is identified, the therapist could assess other patients and treat them if judged necessary. In this context, they could provide either a R-TEP EMDR or short intervention such as reassurance according to therapist assessment.
Study: NCT05117476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLN-619
Description: Anti-MICA/MICB monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLN-619
Description: Anti-MICA/MICB monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLN-619
Description: Anti-MICA/MICB monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLN-619
Description: Anti-MICA/MICB monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Keytruda

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Keytruda
Study: NCT05109312

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 100 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 125 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: 400 mg

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luer lock applicator
Description: Applicator for instillation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luer lock applicator
Description: Applicator for instillation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 400 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 400 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 1 g

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 1 g

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1 g

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1 g
Study: NCT05377632

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic-assisted laparoscopic partial nephrectomy (LPN) or laparoscopic nephrectomy (LN)
Description: laparoscopic partial nephrectomy (LPN) or laparoscopic nephrectomy (LN) include bilateral tumors or tumors in a solitary kidney. Relative indications include familial renal cancer syndromes such as Von Hippel-Lindau, hereditary leiomyomatosis, or hereditary papillary renal cell carcinoma. Patients with chronic kidney disease are generally offered nephron sparing surgery for hope of future renal function preservation. This reasoning also applies to those patients with preexisting diseases that may threaten a solitary kidney such as uncontrolled diabetes and hypertension.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic-assisted laparoscopic partial nephrectomy (LPN) or laparoscopic nephrectomy (LN)
Description: laparoscopic partial nephrectomy (LPN) or laparoscopic nephrectomy (LN) include bilateral tumors or tumors in a solitary kidney. Relative indications include familial renal cancer syndromes such as Von Hippel-Lindau, hereditary leiomyomatosis, or hereditary papillary renal cell carcinoma. Patients with chronic kidney disease are generally offered nephron sparing surgery for hope of future renal function preservation. This reasoning also applies to those patients with preexisting diseases that may threaten a solitary kidney such as uncontrolled diabetes and hypertension.
Study: NCT06273163

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medically tailored meals
Description: Medically tailored meals are nutritious meals formulated for weight wellness.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Noom®
Description: Noom® is a subscription-based mobile application used to support healthy eating and exercise behavior change.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Care is provided at the discretion of the individual provider (e.g., usual care).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Care is provided at the discretion of the individual provider (e.g., usual care).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Care is provided at the discretion of the individual provider (e.g., usual care).
Study: NCT06441799

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home radiofrequency skin treatment instrument
Description: Subjects in the experimental group were treated with the test instrument combined with medical ultrasonic coupler for 5 days a week according to the prescribed use method (duration of use: 10 minutes for the whole face, continuous use twice a day, a total of 20 minutes) for 12 weeks. To evaluate the reduction of wrinkles before and after treatment and the changes of laboratory instruments.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasonic coupler for medical purposes
Description: In control group, medical ultrasonic coupler was evenly applied on face and orbit for 5 days a week (duration: 20 minutes) for 12 consecutive days Week. To evaluate the reduction of wrinkles and the change of laboratory instruments before and after use.
Study: NCT05890703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP2 (lidocaine-23%-tetracaine-7% gel)
Description: Applied in a 2 mm thick even layer for 30 minutes on the ulcer with an occlusive dressing. During the second treatment the same dose is applied. Immediately after removal of the occlusive dressing, the rest of the preparation will be removed and sharp debridement will be performed. In order to minimise bias in this crossover trial, the localisation of start (most distal part of Wound) of sharp debridement and the sequence of sharp debridement (if more than one wound; from the largest to the smallest) is defined in the first visit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IMP1 (EMLA 5% cream)
Description: Applied in a 2 mm thick even layer for 30 minutes on the ulcer with an occlusive dressing. During the second treatment the same dose is applied. Immediately after removal of the occlusive dressing, the rest of the preparation will be removed and sharp debridement will be performed. In order to minimise bias in this crossover trial, the localisation of start (most distal part of Wound) of sharp debridement and the sequence of sharp debridement (if more than one wound; from the largest to the smallest) is defined in the first visit.
Study: NCT05491122

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increasing or decreasing daily total fluid intake
Description: 1-week intervention where the intake of drinking water will either be increased (if habitually low) or decreased (if habitually high). The total fluid intake (TFI) prescriptions during the intervention are derived from the mean TFI of habitually high and habitually low drinkers from a sex, age and country matched population. Specifically, habitually high drinkers will be permitted a TFI of 1.3 L/day and habitually low drinkers will be permitted a TFI of 3.5 L/day for men and 3.3 L/day for women. Participants will be instructed to maintain their usual intake of other beverages i.e., tea/coffee to achieve their target TFI. The diurnal saliva cortisol response at rest will be examined at the end of both experimental periods and the saliva cortisol response to an acute psychological stress will be examined at the end of the habitual experimental period only.
Study: NCT05452603

Intervention type: DEVICE
Intervention: 96-hour off IBP wireless pH monitoring capsule
Description: The endoscopic pH measurement capsule will be placed 6cm above the squamocolumnar junction, determined endoscopically, in the sedated patient. Then the plot will be read.
Study: NCT05634577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitotane
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by vein (IV)